Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm, Corporate Presentation June 2018

Open Briefing June 2018

A clinical-stage oncology drug company developing a disruptive technology for the treatment of solid cancers by radiotherapy and chemotherapy

Unique dual-acting anti-cancer drug

NOX66 Idronoxil (lipophilic form)

- inhibits DNA repair
inhibits PARP-1, topoisomerases 1 and 2

- promotes anti-tumour immunity
increases NK (natural killer) cell activity

To view Presentation please download PDF attached: 
Download this document